Digbi Health has expanded its Precision Biology telehealth platform to include clinical hormone replacement therapy, folding hormonal services in alongside its existing obesity, metabolic, gastrointestinal and inflammatory care. The pitch is that one app and one clinical team now handle both sides of a problem that is usually split across two providers.

GLP-1 care means prescriptions in the peptide-hormone class used for obesity and type 2 diabetes treatment, and hormone replacement therapy means estrogen and related hormonal prescribing, most often around menopause. Women on the platform can get both routes through the same login, with nutrition and lifestyle care personalized to their genetics, gut microbiome, continuous glucose data and advanced blood biomarkers.

Why the bundling matters

The clinical argument for putting these together is reasonable on its face: weight, metabolic health and hormonal change interact, and a patient managing all of it through two unconnected telehealth vendors is the one doing the integration work herself. Whether a single platform produces better outcomes than two good ones is a separate question, and the announcement does not answer it.

Digbi says it is the first to combine gut microbiome, genetic and advanced blood-biomarker testing to personalize HRT. That is a company claim about its own product, not a finding, and it is worth reading as such.

The employer channel

The distribution story is the more interesting half. More than 300 employers and health plans already contract with Digbi and can offer the new services under existing agreements, with many folding them into 2027 plan designs.

The company puts its reach at 30 million individuals through those employers and plans. Benefits channels are how GLP-1 access is actually being rationed in practice, so a vendor that can add hormone therapy without renegotiating contracts has a real structural advantage.

The number that is not there

Digbi says unifying care on one platform reduces per-employee digital health spend, and cites peer-reviewed actuarial claims research showing per-member annual healthcare savings. It does not state the figure.

A savings claim without a dollar amount and a comparison group is a marketing line, however the underlying research is labeled. That is the thing to watch for when the 2027 plan designs land and employers have to justify them.

Where this goes next

What Digbi has announced is a packaging change with a credible commercial logic behind it, not a clinical result. The open question is whether bundled hormonal and GLP-1 care measurably outperforms the fragmented version, and nothing published so far settles it.